In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Q1 2025 Management View CEO Pascal Soriot emphasized that AstraZeneca's total revenue grew by 10% in Q1 2025, with core operating profit increasing by 12% and core EPS by 21%. Growth was supported by ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

A common variant of the PCSK9 gene immediately caught their attention. Present in the germlines of 70 percent of white women, this gene variant was associated with reduced breast cancer survival.

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort ...